

Technology Advisory Interests Register

Topic: Vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy [ID6470]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Mike Chambers	TAC Committee Member	Financial	I have participated in an advisory panel for Pfizer (possible comparator company) in an unrelated disease area: prostate cancer	19/08/2025	It was agreed that Mike's declaration would not prevent them from participating in discussions on this appraisal
Elizabeth Thurgar	TAC Committee Member	Financial	In the last 12 months I have worked with Pfizer in an unrelated indication, NSCLC	19/08/2025	It was agreed that Elizabeth's declaration would not prevent them from participating in discussions on this appraisal
Mark Corbett	TAC Committee Member	Non-financial professional	I work at the York Technology Assessment Group but have played no part in the work on this appraisal.	26/08/2025	It was agreed that Mark's declaration would not prevent them from participating in discussions on this appraisal
Satish Venkateshan	TAC Committee Member	Financial	Regeneron is developing therapeutics for a broad range of diseases including Nexiguran ziclumeran (Nex-z, NTLA-2001) in collaboration with Intellia for transthyretin-related amyloidosis cardiomyopathy. I work for	21/08/2025	It was agreed that Satish's declaration would prevent them from participating in discussions on this appraisal

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Regeneron, pharmaceuticals/biotech company. I also own shares in the company and have stock options.		
Kate Ren	TAC Committee Member	Financial	I led the structured expert elicitation used to inform the survival extrapolation in the economic evaluation for this submission. I also provided consultancy services to Alnylam regarding this submission. In addition, I also provided statistical methodology consultancy service to a possible comparator company Pfizer for an unrelated treatment in an unrelated disease area (Tofacitinib for Moderate-to-Severe Ulcerative Colitis).	23/08/2025	It was agreed that Kate's declaration would prevent them from participating in discussions on this appraisal
Julian Gilmore	Expert	Direct – financial	I undertake consultancy for Alnylam and have been a member of the Advisory Board on some of their trials. PI on a grant from Alnylam to my institution (UCL), 2025	10/02/2025	It was agreed that Julian's declaration would not prevent them from providing expert advice to the committee
William Moody	Expert	Direct - financial	I have received consultancy and / or speaker fees from the following companies in the last 12 months:	15/12/2024	It was agreed that William's declaration would not

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Alnylam, Astra Zeneca, Bayer, Bristol Myers Squibb, Pfizer		prevent them from providing expert advice to the committee
		Indirect	<p>I have led on a tender on behalf of the Trust (UHB) submitted to NHSE in November to become part of a formal NHS England Amyloidosis Network.</p> <p>My trust (UHB) has entered a joint working collaborative agreement with Pfizer and completed a joint working collaborative agreement with Alnylam in 2024</p>		